scFv(PSMA)-CD28-41BB-CD3zeta CAR-T Lentivirus

The scFv(PSMA)-CD28-41BB-CD3zeta CAR-T Lentivirus is a high-titer, replication-deficient viral vector designed for the stable genetic engineering of primary human T lymphocytes. This product encodes a third-generation Chimeric Antigen Receptor (CAR) specifically targeting the Prostate-Specific Membrane Antigen (PSMA), a type II transmembrane glycoprotein that is highly overexpressed in prostate cancer cells and the neovasculature of various solid tumors. The construct features a high-affinity single-chain variable fragment (scFv) linked to a sophisticated intracellular signaling architecture. By incorporating both CD28 and 4-1BB (CD137) costimulatory domains alongside the primary CD3zeta activation moiety, the vector facilitates a synergistic signaling response. This dual-costimulatory design is engineered to optimize T-cell performance, combining the rapid expansion and potent effector functions driven by CD28 with the enhanced metabolic fitness and long-term persistence characteristic of 4-1BB signaling.

This lentiviral system serves as an essential tool in the preclinical development and validation of adoptive cell therapies for metastatic castration-resistant prostate cancer (mCRPC). It is primarily utilized to generate CAR-T cells for standardized potency assays, including in vitro co-culture experiments to measure antigen-specific cytotoxicity and the release of pro-inflammatory cytokines such as IFN-gamma and TNF-alpha. Furthermore, the vector is indispensable for in vivo longitudinal studies using xenograft mouse models to evaluate tumor infiltration, expansion kinetics, and the overall therapeutic index of the engineered cells. Researchers also employ this product to investigate strategies for overcoming the immunosuppressive tumor microenvironment and to study T-cell exhaustion markers in the context of solid tumors. Its high transduction efficiency and reliable transgene expression make it a robust reagent for benchmarking novel therapeutic combinations, such as the integration of CAR-T cells with checkpoint inhibitors or other localized treatment modalities.